Moderna

Moderna

Yahoo Finance • 5 hours ago

12 S&P 500 Stocks Gain The Most From The 'Blue Wave'

Voters made no mystery of how they're feeling about the direction the U.S. is in. And some S&P 500 stocks were clear winners, too. Continue Reading... Full story

Yahoo Finance • 23 hours ago

Sector Update: Healthcare Stocks Rise Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 2.6% and th Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news Full access to Financial Times and MT N... Full story

Yahoo Finance • 2 days ago

iShares Russell Mid-Cap ETF (IWR) Adds Vylor and Hasbro on Friday

This article first appeared on GuruFocus. iShares Russell Mid-Cap ETF (IWR) recorded net buying of $177.6 million in Friday's session, with gross ETF activity of $242.1 million against $58.17 billion in assets under management. IWR increa... Full story

Yahoo Finance • 3 days ago

Earnings live updates: Roku posts earnings beat ahead of acquisition by Fox

The third quarter earnings season is over halfway done, and the reports continue to pour in. This week brings another shot of major earnings courtesy of Apple (AAPL), Palantir (PLTR), and AMD (AMD). In addition to those tech heavyweights,... Full story

Yahoo Finance • 3 days ago

Invesco S&P 500 Equal Weight (RSP) Buys $0.2 Million More Morgan Stanley on Thursday

This article first appeared on GuruFocus. Invesco S&P 500 Equal Weight ETF (RSP) was the lone buyer among the ETFs tracked on Thursday, with no funds selling, as it added to a single position and trimmed 498 others. RSP bought $0.2 millio... Full story

Yahoo Finance • 4 days ago

Jobs, Midterm Elections, Apple, Palantir, McDonald’s, Moderna, and More to Watch This Week

In another busy earnings week, AMD, Estée Lauder, Qualcomm, Pfizer, and many more will report results. We’ll see three readings on jobs this week, as well as data on the manufacturing and services sectors. Continue Reading... Full story

Yahoo Finance • 4 days ago

A big sell-off collides with more Big Tech earnings and a midterm election: What to watch this week

Last week, we opened the Morning Brief newsletter by saying the first week of Big Tech earnings looked promising — until Thursday. This time, we're here to say the second week of Big Tech earnings looked promising — until Tuesday. Lacklus... Full story

Yahoo Finance • 5 days ago

Notable analyst calls this week: Broadcom, Moderna and Abbott among top picks

The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]) closed in the red on Friday, after investors digested corporate results from... Full story

Yahoo Finance • 5 days ago

How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine Data

Merck and Moderna reported Phase 3 data from the INTerpath-001 trial in resected high-risk melanoma, where personalized mRNA therapy intismeran autogene plus KEYTRUDA reduced the risk of recurrence or death by 42% and distant metastasis or... Full story

Yahoo Finance • 7 days ago

Merck Surges 5% On Sales Beat, Outplaying Cancer Vaccine Woes

Dow Jones component Merck hiked its 2026 outlook Thursday on the back of a solid third-quarter report that included a notable Keytruda beat. Continue Reading... Full story

Yahoo Finance • 7 days ago

Merck Beats, But Can Shares Outplay The Cancer Vaccine News?

Dow Jones component Merck hiked its 2026 outlook Thursday on the back of a solid third-quarter report that included a notable Keytruda beat. Continue Reading... Full story

Yahoo Finance • 9 days ago

Moderna shares slip as William Blair cuts rating on valuation after rally

Investing.com -- Moderna Inc (NASDAQ:MRNA) slid 3% in premarket trading after William Blair downgraded the biotechnology company to Market Perform from Outperform, citing valuation constraints following a meteoric run. The downgrade follow... Full story

Yahoo Finance • 10 days ago

Moderna (MRNA) Gets Phase 3 Melanoma Vaccine Validation At ESMO And NEJM

Moderna (NasdaqGS:MRNA) and Merck reported detailed Phase 3 data for their individualized mRNA melanoma vaccine plus KEYTRUDA, intismeran, at ESMO 2026. The Phase 3 trial showed a significant reduction in disease recurrence and distant met... Full story

Yahoo Finance • 10 days ago

Moderna CEO Says Its Cancer Vaccine Isn’t a Disappointment, It’s a Blockbuster

Moderna’s stock tanked Thursday following a data leak for the drugmaker’s cancer-vaccine candidate, which is co-developed with Merck. Continue Reading... Full story

Yahoo Finance • 10 days ago

Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine

Moderna stock yo-yoed Monday on more muted expectations for its Merck-partnered cancer vaccine, INT. Continue Reading... Full story

Yahoo Finance • 10 days ago

Premarket movers: Moderna, Brazil ADRs drop; SpaceX rises

Investing.com - U.S. stock index futures rose on Monday after technology-driven losses battered Wall Street in the previous session, with investors turning their attention to this week's Federal Reserve policy announcement and a slate of m... Full story

Yahoo Finance • 13 days ago

Oncologists Cheer Melanoma Data

Leaked data from Moderna and Merck's highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks.Normally results of such pivotal drug studie... Full story

Yahoo Finance • 13 days ago

Investing.com’s stocks of the week

Investing.com -- Cybersecurity names gained ground on a global software alert while Meta declined and a fresh escalation in the Middle East pushed crude to highs. Still guessing which stocks will beat the market? Our AI portfolio updates... Full story

Yahoo Finance • 13 days ago

Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?

Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data. Continue Reading... Full story

Yahoo Finance • 13 days ago

Moderna’s Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure

Moderna and Merck’s cancer vaccine reduced the risk of melanoma recurrence or death by 42%, but investors questioned its potential across other cancers. Continue Reading... Full story